Abstract
Evidence-based medicine (EBM) aims for the ideal that healthcare professionals make conscientious, explicit, and judicious use of the best available evidence gained from the scientific method to clinical decision-making. It seeks to assess the strength of the evidence for benefits of diagnostic tests and treatments, using techniques from science, engineering, and statistics, such as the systematic review of medical literature, meta-analysis, risk-benefit analysis, and randomized controlled trials. The limited success rate of EBM therapies suggests that the complex nature of hair loss may be inadequately served by the present levels of evidence, and that physicians treating hair loss may have fallen short of adequately researching a robust evidence to underpin their practices. Against this backdrop, the concept of precision medicine (PM) is evolving. PM refers to the customization of medical care to the patient’s individual characteristics based on the patient’s genetic background and other molecular or cellular analysis, while classifying patients into subpopulations that differ in their susceptibility to a particular medical condition, in the biology or prognosis of those medical conditions, or in their response to a specific treatment. With the advances in hair research, the powerful tools of molecular biology and genetics, and innovative technologies, we have the robust scientific data and tools to adapt the concept of PM to the practice of trichiatry. Finally, databases pertaining to the development and efficacy of PM must be analyzed and be used to form the basis of evidence-based personalized trichiatry.
References
1.
Guyatt
G
; Evidence-Based Medicine Working Group
. Evidence-based medicine. A new approach to teaching the practice of medicine
. JAMA
. 1992
Nov
;268
(17
):2420
–5
.
[PubMed]
0098-74842.
Timmerman
L
. What’s in a Name? A Lot, When It Comes to Precision Medicine
. Xconomy
; 2013
.3.
Trüeb
RM
, Vañó-Galván
S
, Kopera
D
, et al. Trichologist, dermato-trichologist, or trichiatrist? A global perspective on a strictly medical discipline
. Skin Appendage Disord
. Forthcoming.2296-91954.
Marcińska
M
, Pośpiech
E
, Abidi
S
, Andersen
JD
, van den Berge
M
, Carracedo
Á
, et al.; EUROFORGEN-NoE Consortium
. Evaluation of DNA variants associated with androgenetic alopecia and their potential to predict male pattern baldness
. PLoS One
. 2015
May
;10
(5
):e0127852
.
[PubMed]
1932-62035.
Wakisaka
N
, Taira
Y
, Ishikawa
M
, Nakamizo
Y
, Kobayashi
K
, Uwabu
M
, et al. Effectiveness of finasteride on patients with male pattern baldness who have different androgen receptor gene polymorphism
. J Investig Dermatol Symp Proc
. 2005
Dec
;10
(3
):293
–4
.
[PubMed]
1087-00246.
Cauci
S
, Chiriacò
G
, Cecchin
E
, Toffoli
G
, Xodo
S
, Stinco
G
, et al. Androgen receptor (AR) gene (CAG)n and (GGN)n length polymorphisms and symptoms in young males with long-lasting adverse effects after finasteride use against androgenic alopecia
. Sex Med
. 2017
Mar
;5
(1
):e61
–71
.
[PubMed]
2050-11617.
Goren
A
, Castano
JA
, McCoy
J
, Bermudez
F
, Lotti
T
. Novel enzymatic assay predicts minoxidil response in the treatment of androgenetic alopecia
. Dermatol Ther (Heidelb)
. 2014
May-Jun
;27
(3
):171
–3
.
[PubMed]
2193-82108.
Roberts
J
, Desai
N
, McCoy
J
, Goren
A
. Sulfotransferase activity in plucked hair follicles predicts response to topical minoxidil in the treatment of female androgenetic alopecia
. Dermatol Ther (Heidelb)
. 2014
Jul-Aug
;27
(4
):252
–4
.
[PubMed]
2193-82109.
Goren
A
, Shapiro
J
, Roberts
J
, McCoy
J
, Desai
N
, Zarrab
Z
, et al. Clinical utility and validity of minoxidil response testing in androgenetic alopecia
. Dermatol Ther (Heidelb)
. 2015
Jan-Feb
;28
(1
):13
–6
.
[PubMed]
2193-821010.
Deloche
C
, de Lacharrière
O
, Misciali
C
, Piraccini
BM
, Vincenzi
C
, Bastien
P
, et al. Histological features of peripilar signs associated with androgenetic alopecia
. Arch Dermatol Res
. 2004
Mar
;295
(10
):422
–8
.
[PubMed]
0340-369611.
Whiting
DA
. Diagnostic and predictive value of horizontal sections of scalp biopsy specimens in male pattern androgenetic alopecia. J Am Acad Dermatol 1993
;28(5 Pt 1):755-63 312.
Schwartz
JR
, Henry
JP
, Kerr
KM
, Flagler
MJ
, Page
SH
, Redman-Furey
N
. Incubatory environment of the scalp impacts pre-emergent hair to affect post-emergent hair cuticle integrity
. J Cosmet Dermatol
. 2017
May
;•••
: ; [Epub ahead of print
].
[PubMed]
1473-213013.
Reichel
M
, Heisig
P
, Kampf
G
. Identification of variables for aerobic bacterial density at clinically relevant skin sites
. J Hosp Infect
. 2011
May
;78
(1
):5
–10
.
[PubMed]
0195-670114.
DeAngelis
YM
, Gemmer
CM
, Kaczvinsky
JR
, Kenneally
DC
, Schwartz
JR
, Dawson
TL
Jr. Three etiologic facets of dandruff and seborrheic dermatitis: malassezia fungi, sebaceous lipids, and individual sensitivity
. J Investig Dermatol Symp Proc
. 2005
Dec
;10
(3
):295
–7
.
[PubMed]
1087-002415.
Gomez-Moyano
E
, Crespo-Erchiga
V
, Martínez-Pilar
L
, Godoy Diaz
D
, Martínez-García
S
, Lova Navarro
M
, Vera Casaño
A.
Do Malassezia species play a role in exacerbation of scalp psoriasis? J Mycol Med. 2014
;24:87-92 26.16.
Waersted
A
, Hjorth
N
. Pityrosporum orbiculare—a pathogenic factor in atopic dermatitis of the face, scalp and neck?
Acta Derm Venereol Suppl (Stockh)
. 1985
;114
:146
–8
.
[PubMed]
0365-834117.
Kim
TY
, Jang
IG
, Park
YM
, Kim
HO
, Kim
CW
. Head and neck dermatitis: the role of Malassezia furfur, topical steroid use and environmental factors in its causation
. Clin Exp Dermatol
. 1999
May
;24
(3
):226
–31
.
[PubMed]
0307-693818.
Schmid-Grendelmeier
P
, Scheynius
A
, Crameri
R
. The role of sensitization to Malassezia sympodialis in atopic eczema
. Chem Immunol Allergy
. 2006
;91
:98
–109
.
[PubMed]
1660-224219.
Darabi
K
, Hostetler
SG
, Bechtel
MA
, Zirwas
M
. The role of Malassezia in atopic dermatitis affecting the head and neck of adults
. J Am Acad Dermatol
. 2009
Jan
;60
(1
):125
–36
.
[PubMed]
0190-962220.
Brodská
P
, Panzner
P
, Pizinger
K
, Schmid-Grendelmeier
P
. IgE-mediated sensitization to malassezia in atopic dermatitis: more common in male patients and in head and neck type
. Dermatitis
. 2014
May-Jun
;25
(3
):120
–6
.
[PubMed]
1710-356821.
Vexiau
P
, Chaspoux
C
, Boudou
P
, Fiet
J
, Jouanique
C
, Hardy
N
, et al. Effects of minoxidil 2% vs. cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12-month randomized trial
. Br J Dermatol
. 2002
Jun
;146
(6
):992
–9
.
[PubMed]
0007-096322.
Price
VH
, Roberts
JL
, Hordinsky
M
, Olsen
EA
, Savin
R
, Bergfeld
W
, et al. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia
. J Am Acad Dermatol
. 2000
Nov
;43
(5 Pt 1
):768
–76
.
[PubMed]
0190-962223.
Shum
KW
, Cullen
DR
, Messenger
AG
. Hair loss in women with hyperandrogenism: four cases responding to finasteride
. J Am Acad Dermatol
. 2002
Nov
;47
(5
):733
–9
.
[PubMed]
0190-962224.
Trüeb
RM
; Swiss Trichology Study Group
. Finasteride treatment of patterned hair loss in normoandrogenic postmenopausal women
. Dermatology
. 2004
;209
(3
):202
–7
.
[PubMed]
1018-866525.
Iorizzo
M
, Vincenzi
C
, Voudouris
S
, Piraccini
BM
, Tosti
A
. Finasteride treatment of female pattern hair loss
. Arch Dermatol
. 2006
Mar
;142
(3
):298
–302
.
[PubMed]
0003-987X26.
Yeon
JH
, Jung
JY
, Choi
JW
, Kim
BJ
, Youn
SW
, Park
KC
, et al. 5 mg/day finasteride treatment for normoandrogenic Asian women with female pattern hair loss
. J Eur Acad Dermatol Venereol
. 2011
Feb
;25
(2
):211
–4
.
[PubMed]
0926-995927.
Boychenko
O
, Bernstein
RM
, Schweiger
ES
. Finasteride in the treatment of female pattern (androgenic) alopecia: a case report and review of the literature
. Cutis
. 2012
Aug
;90
(2
):73
–6
.
[PubMed]
0011-416228.
Oliveira-Soares
R
, E Silva
JM
, Correia
MP
, André
MC
. Finasteride 5 mg/day Treatment of Patterned Hair Loss in Normo-androgenetic Postmenopausal Women
. Int J Trichology
. 2013
Jan
;5
(1
):22
–5
.
[PubMed]
0974-775329.
Won
YY
, Lew
BL
, Sim
WY
. Clinical efficacy of oral administration of finasteride at a dose of 2.5 mg/day in women with female pattern hair loss
. Dermatol Ther (Heidelb)
. 2018
Mar
;31
(2
):e12588
.
[PubMed]
2193-821030.
Olsen
EA
, Hordinsky
M
, Roberts
JL
, Whiting
DA
; Dermatologic Consortium for Women’s Health
. Female pattern hair loss
. J Am Acad Dermatol
. 2002
Nov
;47
(5
):795
.
[PubMed]
0190-962231.
Jackson
D
, Church
RE
, Ebling
FJ
. Hair diameter in female baldness
. Br J Dermatol
. 1972
Oct
;87
(4
):361
–7
.
[PubMed]
0007-096332.
Schmidt
JB
, Lindmaier
A
, Spona
J
. [Hyperprolactinemia and hypophyseal hypothyroidism as cofactors in hirsutism and androgen-induced alopecia in women]
. Hautarzt
. 1991
Mar
;42
(3
):168
–72
.
[PubMed]
0017-847033.
Schmidt
JB
. Hormonal basis of male and female androgenic alopecia: clinical relevance
. Skin Pharmacol
. 1994
;7
(1-2
):61
–6
.
[PubMed]
1011-028334.
Arafah
BM
. Increased need for thyroxine in women with hypothyroidism during estrogen therapy
. N Engl J Med
. 2001
Jun
;344
(23
):1743
–9
.
[PubMed]
0028-479335.
Schindler
AE
. Thyroid function and postmenopause
. Gynecol Endocrinol
. 2003
Feb
;17
(1
):79
–85
.
[PubMed]
0951-359036.
del Ghianda
S
, Tonacchera
M
, Vitti
P
. Thyroid and menopause
. Climacteric
. 2014
Jun
;17
(3
):225
–34
.
[PubMed]
1369-713737.
Aydingöz
IE
, Ferhanoğlu
B
, Güney
O
. Does tissue iron status have a role in female alopecia?
J Eur Acad Dermatol Venereol
. 1999
Jul
;13
(1
):65
–7
.
[PubMed]
0926-995938.
Chamberlain
AJ
, Dawber
RP
. Significance of iron status in hair loss in women
. Br J Dermatol
. 2003
Aug
;149
(2
):428
.
[PubMed]
0007-096339.
Rushton
DH
. Decreased serum ferritin and alopecia in women
. J Invest Dermatol
. 2003
Nov
;121
(5
):xvii
–xviii
.
[PubMed]
0022-202X40.
Kantor
J
, Kessler
LJ
, Brooks
DG
, Cotsarelis
G
. Decreased serum ferritin is associated with alopecia in women
. J Invest Dermatol
. 2003
Nov
;121
(5
):985
–8
.
[PubMed]
0022-202X41.
Trost
LB
, Bergfeld
WF
, Calogeras
E
. The diagnosis and treatment of iron deficiency and its potential relationship to hair loss
. J Am Acad Dermatol
. 2006
May
;54
(5
):824
–44
.
[PubMed]
0190-962242.
Rushton
DH
, Dover
R
, Norris
MJ
, Gilkes
JJ
. Iron and hair loss in women; what is deficiency? This is the real question!
J Am Acad Dermatol
. 2007
Mar
;56
(3
):518
–9
.
[PubMed]
0190-962243.
Deloche
C
, Bastien
P
, Chadoutaud
S
, Galan
P
, Bertrais
S
, Hercberg
S
, et al. Low iron stores: a risk factor for excessive hair loss in non-menopausal women
. Eur J Dermatol
. 2007
Nov-Dec
;17
(6
):507
–12
.
[PubMed]
1167-112244.
Bregy
A
, Trueb
RM
. No association between serum ferritin levels [{GT}]10 microg/l and hair loss activity in women
. Dermatology
. 2008
;217
(1
):1
–6
.
[PubMed]
1018-866545.
Moeinvaziri
M
, Mansoori
P
, Holakooee
K
, Safaee Naraghi
Z
, Abbasi
A
. Iron status in diffuse telogen hair loss among women
. Acta Dermatovenerol Croat
. 2009
;17
(4
):279
–84
.
[PubMed]
1330-027X46.
St Pierre
SA
, Vercellotti
GM
, Donovan
JC
, Hordinsky
MK
. Iron deficiency and diffuse nonscarring scalp alopecia in women: more pieces to the puzzle
. J Am Acad Dermatol
. 2010
Dec
;63
(6
):1070
–6
.
[PubMed]
0190-962247.
Olsen
EA
, Reed
KB
, Cacchio
PB
, Caudill
L
. Iron deficiency in female pattern hair loss, chronic telogen effluvium, and control groups
. J Am Acad Dermatol
. 2010
Dec
;63
(6
):991
–9
.
[PubMed]
0190-962248.
Park
SY
, Na
SY
, Kim
JH
, Cho
S
, Lee
JH
. Iron plays a certain role in patterned hair loss
. J Korean Med Sci
. 2013
Jun
;28
(6
):934
–8
.
[PubMed]
1011-893449.
Tosti
A
, Bellavista
S
, Iorizzo
M
. Alopecia areata: a long term follow-up study of 191 patients
. J Am Acad Dermatol
. 2006
Sep
;55
(3
):438
–41
.
[PubMed]
0190-962250.
Ikeda
T
. A new classification of alopecia areata
. Dermatologica
. 1965
;131
(6
):421
–45
.
[PubMed]
0011-907551.
Cunliffe
WJ
, Hall
R
, Newell
DJ
, Stevenson
CJ
. Vitiligo, thyroid disease and autoimmunity
. Br J Dermatol
. 1968
Mar
;80
(3
):135
–9
.
[PubMed]
0007-096352.
Cunliffe
WJ
, Hall
R
, Stevenson
CJ
, Weightman
D
. Alopecia areata, thyroid disease and autoimmunity
. Br J Dermatol
. 1969
Dec
;81
(12
):877
–81
.
[PubMed]
0007-096353.
Puavilai
S
, Puavilai
G
, Charuwichitratana
S
, Sakuntabhai
A
, Sriprachya-Anunt
S
. Prevalence of thyroid diseases in patients with alopecia areata
. Int J Dermatol
. 1994
Sep
;33
(9
):632
–3
.
[PubMed]
0011-905954.
Seyrafi
H
, Akhiani
M
, Abbasi
H
, Mirpour
S
, Gholamrezanezhad
A
. Evaluation of the profile of alopecia areata and the prevalence of thyroid function test abnormalities and serum autoantibodies in Iranian patients
. BMC Dermatol
. 2005
Oct
;5
(1
):11
.
[PubMed]
1471-594555.
Kumar
B
, Sharma
VK
, Sehgal
S
. Antismooth muscle and antiparietal cell antibodies in Indians with alopecia areata
. Int J Dermatol
. 1995
Aug
;34
(8
):542
–5
.
[PubMed]
0011-905956.
Werth
VP
, White
WL
, Sanchez
MR
, Franks
AG
. Incidence of alopecia areata in lupus erythematosus
. Arch Dermatol
. 1992
Mar
;128
(3
):368
–71
.
[PubMed]
0003-987X57.
Corazza
GR
, Andreani
ML
, Venturo
N
, Bernardi
M
, Tosti
A
, Gasbarrini
G
. Celiac disease and alopecia areata: report of a new association
. Gastroenterology
. 1995
Oct
;109
(4
):1333
–7
.
[PubMed]
0016-508558.
Fessatou
S
, Kostaki
M
, Karpathios
T
. Coeliac disease and alopecia areata in childhood
. J Paediatr Child Health
. 2003
Mar
;39
(2
):152
–4
.
[PubMed]
1034-481059.
Zampetti
M
, Filippetti
R
. Alopecia areata and celiac disease
. G Ital Dermatol Venereol
. 2008
Apr
;143
(2
):168
.
[PubMed]
0392-048860.
Ertekin
V
, Tosun
MS
, Erdem
T
. Screening of celiac disease in children with alopecia areata
. Indian J Dermatol
. 2014
May
;59
(3
):317
.
[PubMed]
0019-515461.
Park
H
, Kim
CW
, Kim
SS
, Park
CW
. The therapeutic effect and the changed serum zinc level after zinc supplementation in alopecia areata patients who had a low serum zinc level
. Ann Dermatol
. 2009
May
;21
(2
):142
–6
.
[PubMed]
1013-908762.
Abdel Fattah
NS
, Atef
MM
, Al-Qaradaghi
SM
. Evaluation of serum zinc level in patients with newly diagnosed and resistant alopecia areata
. Int J Dermatol
. 2016
Jan
;55
(1
):24
–9
.
[PubMed]
0011-905963.
Yilmaz
N
, Serarslan
G
, Gokce
C
. Vitamin D concentration are decreased in patients with alopecia areata
. Vitam Trace Elem
. 2012
;1
(04
):105
–9
. 64.
d’Ovidio
R
, Vessio
M
, d’Ovidio
FD
. Reduced level of 25-hydroxyvitamin D in chronic/relapsing Alopecia Areata
. Dermatoendocrinol
. 2013
Apr
;5
(2
):271
–3
.
[PubMed]
1938-197265.
Aksu Cerman
A
, Sarikaya Solak
S
, Kivanc Altunay
I
. Vitamin D deficiency in alopecia areata
. Br J Dermatol
. 2014
Jun
;170
(6
):1299
–304
.
[PubMed]
0007-096366.
Bakry
OA
, El Farargy
SM
, El Shafiee
MK
, Soliman
A
. Serum Vitamin D in patients with alopecia areata
. Indian Dermatol Online J
. 2016
Sep-Oct
;7
(5
):371
–7
.
[PubMed]
2229-517867.
Stewart
MI
, Smoller
BR
. Alopecia universalis in an HIV-positive patient: possible insight into pathogenesis
. J Cutan Pathol
. 1993
Apr
;20
(2
):180
–3
.
[PubMed]
0303-698768.
Price
VH
, Colombe
BW
. Heritable factors distinguish two types of alopecia areata
. Dermatol Clin
. 1996
Oct
;14
(4
):679
–89
.
[PubMed]
0733-863569.
Petukhova
L
, Duvic
M
, Hordinsky
M
, Norris
D
, Price
V
, Shimomura
Y
, et al. Genome-wide association study in alopecia areata implicates both innate and adaptive immunity
. Nature
. 2010
Jul
;466
(7302
):113
–7
.
[PubMed]
0028-083670.
Betz
RC
, Petukhova
L
, Ripke
S
, Huang
H
, Menelaou
A
, et al. Genome-wide meta-analysis in alopecia areata resolves HLA associations and reveals two new susceptibility loci.
Nat Commun. 2015
;22;6:5966 71.
Divito
SJ
, Kupper
TS
. Inhibiting Janus kinases to treat alopecia areata
. Nat Med
. 2014
Sep
;20
(9
):989
–90
.
[PubMed]
1078-895672.
Craiglow
BG
, King
BA
. Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis
. J Invest Dermatol
. 2014
Dec
;134
(12
):2988
–90
.
[PubMed]
0022-202X73.
Xing
L
, Dai
Z
, Jabbari
A
, Cerise
JE
, Higgins
CA
, Gong
W
, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition
. Nat Med
. 2014
Sep
;20
(9
):1043
–9
.
[PubMed]
1078-895674.
Jabbari
A
, Dai
Z
, Xing
L
, Cerise
JE
, Ramot
Y
, Berkun
Y
, et al. Reversal of alopecia areata following treatment with the JAK1/2 inhibitor Baricitinib
. EBioMedicine
. 2015
Feb
;2
(4
):351
–5
.
[PubMed]
2352-396475.
Liu
LY
, Craiglow
BG
, Dai
F
, King
BA
. Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients
. J Am Acad Dermatol
. 2017
Jan
;76
(1
):22
–8
.
[PubMed]
0190-962276.
Craiglow
BG
, Liu
LY
, King
BA
. Tofacitinib for the treatment of alopecia areata and variants in adolescents
. J Am Acad Dermatol
. 2017
Jan
;76
(1
):29
–32
.
[PubMed]
0190-962277.
Matard
B
, Meylheuc
T
, Briandet
R
, Casin
I
, Assouly
P
, Cavelier-balloy
B
, et al. First evidence of bacterial biofilms in the anaerobe part of scalp hair follicles: a pilot comparative study in folliculitis decalvans
. J Eur Acad Dermatol Venereol
. 2013
Jul
;27
(7
):853
–60
.
[PubMed]
0926-995978.
Parlette
EC
, Kroeger
N
, Ross
EV
. Nd:YAG laser treatment of recalcitrant folliculitis decalvans
. Dermatol Surg
. 2004
Aug
;30
(8
):1152
–4
.
[PubMed]
1076-051279.
Meesters
AA
, Van der Veen
JP
, Wolkerstorfer
A
. Long-term remission of folliculitis decalvans after treatment with the long-pulsed Nd:YAG laser
. J Dermatolog Treat
. 2014
Apr
;25
(2
):167
–8
.
[PubMed]
0954-663480.
Trüeb
RM
, Pericin
M
, Hafner
J
, Burg
G
. [Tufted hair folliculitis]
. Hautarzt
. 1997
Apr
;48
(4
):266
–9
.
[PubMed]
0017-847081.
Karnik
P
, Tekeste
Z
, McCormick
TS
, Gilliam
AC
, Price
VH
, Cooper
KD
, et al. Hair follicle stem cell-specific PPARgamma deletion causes scarring alopecia
. J Invest Dermatol
. 2009
May
;129
(5
):1243
–57
.
[PubMed]
0022-202X82.
Harries
MJ
, Paus
R
. Scarring alopecia and the PPAR-gamma connection
. J Invest Dermatol
. 2009
May
;129
(5
):1066
–70
.
[PubMed]
0022-202X83.
Mirmirani
P
, Karnik
P
. Lichen planopilaris treated with a peroxisome proliferator-activated receptor gamma agonist
. Arch Dermatol
. 2009
Dec
;145
(12
):1363
–6
.
[PubMed]
0003-987X84.
Feinstein
AR
. The pre-therapeutic classification of co-morbidity in chronic disease
. J Chronic Dis
. 1970
Dec
;23
(7
):455
–68
.
[PubMed]
0021-968185.
Valderas
JM
, Starfield
B
, Sibbald
B
, Salisbury
C
, Roland
M
. Defining comorbidity: implications for understanding health and health services
. Ann Fam Med
. 2009
Jul-Aug
;7
(4
):357
–63
.
[PubMed]
1544-170986.
Mangin
D
, Heath
I
, Jamoulle
M
. Beyond diagnosis: rising to the multimorbidity challenge
. BMJ
. 2012
Jun
;344
jun13 2
:e3526
.
[PubMed]
0959-813887.
Jakovljević
M
, Ostojić
L
. Comorbidity and multimorbidity in medicine today: challenges and opportunities for bringing separated branches of medicine closer to each other
. Psychiatr Danub
. 2013
Jun
;25
Suppl 1
:18
–28
.
[PubMed]
0353-505388.
Sandhu
C
, Qureshi
A
, Emili
A
. Panomics for Precision Medicine
. Trends Mol Med
. 2018
Jan
;24
(1
):85
–101
.
[PubMed]
1471-4914© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
